Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted therapy for lung cancer: Beyond EGFR and ALK.

Cancer - 15 Jun 2023

Herrera-Juárez Mercedes, Serrano-Gómez Cristina, Bote-de-Cabo Helena, Paz-Ares Luis

Abstract excerpt

Precision oncology comprises the set of strategies that aim to design the best cancer treatment based on tumor biology. A recognized subset of patients with non-small cell lung cancer (NSCLC) harbor actionable genomic aberrations that can benefit from targeted therapy. In lung cancer, epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are well characterized...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Mutation

Share to Precision Medicine

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 37073562
DOI: 10.1002/cncr.34757

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted therapy for lung cancer: Beyond EGFR and ALK.PMID 37073562Read ↗

Targeted Therapy for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Current Landscape of Targeted Therapy in Lung Cancer.Semantic proximity Read ↗

Targeted therapy for non-small-cell lung cancer: past, present and future.Semantic proximity Read ↗

Targeted therapies and immunotherapy in non-small-cell lung cancerSemantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.Semantic proximity Read ↗

Targeted Therapies in Non-Small Cell Lung Cancer: A Contemporary Review.Semantic proximity Read ↗

Advancements in NSCLC: From Pathophysiological Insights to Targeted Treatments.Semantic proximity Read ↗

NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.Semantic proximity Read ↗

Molecular Targets Beyond the Big 3.Semantic proximity Read ↗

Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enough.Semantic proximity Read ↗

Oncogenic alterations in advanced NSCLC: a molecular super-highwaySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.